Companies: 10,795·Total market cap: $144.5T
PTC Therapeutics, Inc.

PTC Therapeutics, Inc.

PTCTNASDAQHealthcare● Active
$70.87
$-0.10(-0.14%)
Market Cap$5.9B
P/E Ratio
52W High$87.5
52W Low$43.175

PTC Therapeutics, Inc. (PTCT) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

ptct · stock forecast · 26 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 26 Wall Street analysts in the past 3 months

SellBuy

Buy

26 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
17
Hold
7
Sell
2
Strong Sell
0
Total: 26 · Buy rate: 65.4%

12-Month Price Target

High

$120

Consensus

$95.83

+37.1% upside

Low

$82.00

Median: $90 · Last Close: $69.88

The PTC Therapeutics, Inc. (PTCT) analyst consensus is Buy, based on ratings from 26 Wall Street analysts over the past 3 months. The average 12-month PTCT price target is $95.83, representing +37.1% upside from the current price of $69.88.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $96 (37.1%)

Consensus Target

$95.83

37.1% upside

High Target

$120

71.7%

Low Target

$82

17.3%

Current Price

$69.88

as of today

Based on analyst price targets, the PTCT stock price prediction for the next 12 months ranges from $82 to $120. The consensus PTCT price forecast of $95.83 implies 37.1% upside from the current price of $69.88.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$68.811.53%

1-day model range: $68.32–$69.3. Peak: $69.3 (-1.53%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$87+25.0%
2028$100+43.8%
2029$110+56.7%
2030$115+65.2%
2031+70.5%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

43%7%50%
6Buy
1Neutral
7Sell
RSI (14)49.3Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · PTCT · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$69.68BUY
MA 10$70.54SELL
MA 20$71.25SELL
MA 50$69.84BUY
MA 100$69.97SELL
MA 200$69.26BUY
Current $PTCT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$70.31SELL
EMA 10$70.44SELL
EMA 20$70.38SELL
EMA 50$70.00SELL
EMA 100$69.71BUY
EMA 200$66.87BUY
Current $PTCT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Jefferies2026-05-27
Upgrade ↑
HoldBuy
RBC Capital2026-05-08
Maintains
Sector PerformSector Perform
TD Cowen2026-05-08
Upgrade ↑
HoldBuy
Wells Fargo2026-05-08
Maintains
OverweightOverweight
Jefferies2026-03-30
Downgrade ↓
BuyHold
Morgan Stanley2026-02-23
Maintains
OverweightOverweight
RBC Capital2026-02-20
Maintains
Sector PerformSector Perform
B of A Securities2026-02-20
Maintains
BuyBuy
Wells Fargo2026-02-20
Maintains
OverweightOverweight
Barclays2026-01-28
Upgrade ↑
Equal WeightOverweight

Wall Street analysts have recently issued updated ratings on PTC Therapeutics, Inc. (PTCT) stock. Of the recent 251 rating actions, 24 were upgrades and 29 were downgrades. 26 analysts currently cover PTCT.

Analyst Recommendation Trends

Buy ratings23↑ +1
Hold ratings312
Sell ratings101

PTCT analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 3 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$1.2B

↓ 23.9% YoY

Revenue Next Year

$1.3B

↑ 11.2% YoY

EPS This Year

$0.65

EPS Next Year

$2.16

↑ 235.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast PTCT EPS of $0.65 for the current fiscal year, based on estimates from 8 analysts. The PTCT revenue forecast is $1.2B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The PTCT stock forecast is supported by two independent data sources: analyst consensus ratings from 26 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PTCT price target is $95.83 (+37.1% upside), with an analyst consensus of Buy.

The PTCT short-term stock prediction for tomorrow is $68.81 (-1.53%). The PTCT stock price prediction for 2027 estimates an average of $87. The PTCT stock prediction for 2030 projects a range of $106–$124.

PTC Therapeutics, Inc. trades on NASDAQ under the ticker PTCT. The PTCT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 65% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

PTCT forecast · 8 questions

According to 26 Wall Street analysts, the average 12-month PTCT price target is $95.83, with a high forecast of $120.00 and a low of $82.00. The median price target is shown in the chart above when available. This implies +37.1% potential upside from the current price of $69.88.

PTCT price targetWhat is PTCT price targetPTCT analyst price targetPTCT 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.